logo
Plus   Neg
Share
Email

Grafton Group H1 LFL Revenue Up 3.9%; FY Expectations Broadly Unchanged

Grafton Group Plc (GFTU.L) said, for the half year to 30 June 2019, Group revenue increased by 2.4 percent to 1.48 billion pounds from 1.45 billion pounds, prior year, or up by 2.6 percent in constant currency. Like-for-like Group revenue increased by 3.9 percent. The Group noted that its trading in May and June was measured against very strong prior year comparatives. The interim results will be announced on 30 August 2019.

Looking forward, the Group said its current expectations for full year profitability, including the benefit of the recently completed Polvo acquisition, remain broadly unchanged.

Gavin Slark, CEO of Grafton Group said: "Following a strong start to the year Grafton saw some easing of trends in recent months. We expect a continuation of the positive trading conditions in our markets in Ireland and the Netherlands. Activity over the summer in the UK will be an important determinant of momentum entering the significant trading months of September through to November."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Expedia Group Inc.(EXPE) plans to eliminate about 12 percent of its workforce or 3,000 jobs, following its disappointing 2019 business performance, according to reports citing an internal email from Expedia. The Job cuts will include around 500 at its Seattle headquarters. Cargill, a privately-held food and agriculture company, said Monday it will launch new private label plant-based patties and ground products in order to meet the growing global demand for protein. The new products will hit retailers and restaurants in early April. Cargill said that the plant-based protein products were developed through extensive consumer research and innovation. Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled certain lots of seizure medication Phenytoin in the form of oral suspension for potential underdosing or overdosing, the U.S. Food and Drug Administration said in a statement. The company found that the oral suspension may not re-suspend when shaken.
RELATED NEWS
Follow RTT
>